ArticleOncotarget2017

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Maryam Zanjirband et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.